Lupin and Honeywell Partner to Revolutionize Respiratory Care with Eco-Friendly Inhalers
Mumbai: Global pharma major Lupin Limited has announced a groundbreaking partnership with Honeywell to develop next-generation inhalers using Honeywell’s Solstice Air propellant. This innovative technology aims to transform respiratory care for patients with asthma and chronic obstructive pulmonary disease (COPD) while minimizing environmental impact.
Lupin will become the first pharmaceutical company in India to integrate Honeywell’s Solstice Air product at scale in pressurized metered-dose inhalers (pMDIs). Solstice Air offers a near-zero global warming potential alternative to traditional hydrofluorocarbon-based propellants, reducing greenhouse gas emissions by up to 99.9%. This partnership underscores Lupin’s commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for patients and communities worldwide.
Commitment to Sustainability and Patient Care
According to Vinita Gupta, CEO Lupin, “Lupin’s partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide.” Ashish Modi, President, Honeywell India, added, “Solstice Air can play a critical role in ensuring that Lupin’s respiratory inhalers provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions.”
The terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin. This partnership marks a significant step towards reducing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD.
